Rebounds are not limited to basketball. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout. Rebounds are not limited to basketball. Dr Sarah Hull examines the rebound effect in the Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study. What are the outcomes of continued atropine treatment, and what is the ideal concentration? View article hereSarah Hull is a UK-trained Ophthalmologist who completed a PhD in paediatric retinal genetics at UCL and Moorfields in 2016. She has been living in New Zealand since 2018, working as a consultant Ophthalmologist specialising in paediatrics, strabismus and genetics at Auckland District Health Board and Auckland Eye. She is also a Senior Lecturer at Auckland University. Her research focuses on inherited eye disease as well as optic neuropathies.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related